ACTRN12621001410842招募中未知
Phase II Clinical Trial of the Feasibility of Hyper-Accelerated Partial Breast Radiotherapy in Women with Invasive Non-Lobular Breast Carcinoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 640
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 40 Years 至 o limit（—）
- 性别
- Female
入选标准
- •a)Women, aged 40 years and above.
- •b)Performance status 0-2.
- •c)Unicentric, invasive breast carcinoma of non-lobular histology with a maximal microscopic dimension of less than or equal to 3cm.
- •d)Treated with breast conserving surgery.
- •e)Bilateral breast imaging with mammograms and ultrasound scans no longer than 3 months prior to surgery.
- •f)Negative radial resection margins either from primary excision or re-excision, defined as:
- •no tumour at inked margin for the invasive tumour component and
- •greater than or equal to 2mm from the inked margin for the associated intraductal tumour component.
- •Patients with positive resection margins at either superficial or deep margins are still eligible if the surgeon confirms that all intervening breast tissue has been removed from the subcutaneous tissue or the pectoralis fascia.
- •g)No extensive intraductal component (EIC), defined as intraductal component constituting greater than or equal to 25% of the primary tumour with intraductal foci and/or adjacent to the primary tumour.
- •h)No lymphovascular invasion (LVI), defined as carcinoma cells present within a definite, endothelial-lined space (lymphatic and/or blood vessel), in peri-tumoural tissues.
- •Possible or suspicious LVI, defined as carcinoma cells present within a space with the appearance of a vessel but without a recognisable endothelial lining, is allowed.
- •i)No cutaneous involvement, including Paget’s disease of the nipple, oedema (peau d’orange), satellite skin nodules, skin ulceration or inflammatory carcinoma.
- •j)Oestrogen receptor positive.
- •k)Human epidermal growth factor receptor 2 (HER-2) negative, as determined by immunohistochemistry (IHC) staining and/or dual in-situ hybridisation (D-ISH) techniques.
- •l)Negative axillary lymph node involvement on histopathology, classified as either:
- •no tumour cells OR
- •isolated tumour cells (ITC), defined by a single or cluster of tumour cells, no larger than 0.2mm in maximal dimension.
- •m)Clearly defined surgical excision cavity on both assessment ultrasound and computed tomography (CT) scans.
- •n)Ratio of excision cavity volume to the whole breast volume less than or equal to 25%, defined on the assessment CT scan.
- •o)Willingness to give written informed consent.
- •p)Willingness to participate and comply with the study protocol.
排除标准
- •a)Multifocal or multicentric breast cancer.
- •b)Inability to determine microscopic resection margins of the primary breast cancer.
- •c)Locally recurrent breast cancer.
- •d)History of prior malignancies, except for non-melanomatous skin cancer, carcinoma in-situ of the uterine cervix or contralateral invasive non-lobular breast cancer.
- •e)Pre-existing connective tissue disorder, such as scleroderma, systemic lupus erythematosis and dermatomyositis.
- •f)Prior radiation treatment to the ipsilateral breast or thoracic region.
- •g)Women who are lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
- •h)Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.
- •i)Patients who are unwilling to have their blood or tissue samples collected and stored for further genetic testing.
研究者
相似试验
已完成
不适用
Phase III study on the efficacy and safety of Hypericum extract WS® 5570 in patients with a Major Depressive EpisodeMajor depressive disorderMental and Behavioural DisordersDepressionISRCTN77277298Schwabe Pharmaceuticals (Germany)320
尚未招募
2 期
A Clinical trial to study the effect of two drugs, Ropivacaine and Bupivacaine in patient undergoing lower limb surgeryCTRI/2024/07/070422B J Medical College and Civil Hospital Ahmedabad Government of Gujarat
进行中（未招募）
1 期
Clinical Trial of allogeneic mesenchymal cells from umbilical cord tissue in patients with COVID-19.EUCTR2020-001450-22-ESFundación de Investigación del Hospital Infantil Universitario Niño Jesús106
进行中（未招募）
不适用
Cabozantinib in patients previously treated with immune checkpoint inhibitorsNeoplasmsKCT0005238Asan Medical Center48
进行中（未招募）
1 期
Phase II clinical trial evaluating the efficacy of PF-05212384 (PKI-587) for patients with myeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) or de novo relapsed or refractory AMMyeloid neoplasm secondary to chemo-radiotherapy (t-AML/MDS) /or relapsed or refractory de novo AML /or de novo AML at diagnostic considered unfit to benefit from induction therapy with chemotherapy associated aplasiaMedDRA version: 17.1Level: LLTClassification code 10066572Term: AML progressionSystem Organ Class: 100000004864EUCTR2014-002752-50-FRINSTITUT CURIE